Achilles Therapeutics plc ACHL shares are trading higher on Tuesday after the company announced a $12 million deal with AstraZeneca PLC AZN and plans to cut jobs.

Achilles Therapeutics ACHL股价周二上涨，此前该公司宣布与阿斯利康公司AZN达成1200万美元的交易，并计划裁员。

The agreement involves the transfer of the commercial license for data and tumor samples from Achilles’ TRACERx Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca.

该协议涉及将Achilles的TRACERx非小细胞肺癌（NSCLC）研究的数据和肿瘤样本的商业许可证转让给阿斯利康。

The million deal signals the conclusion of Achilles’ strategic review, which was announced in September 2024.

这笔交易标志着Achilles战略评估的结束，该评估于2024年9月宣布。

In the wake of the deal’s completion, Achilles also rvealed plans to reduce its employee headcount and trim its Board of Directors, while staying compliant with Nasdaq and SEC requirements.

交易完成后，Achilles还保留了减少员工人数和精简董事会的计划，同时遵守纳斯达克和SEC的要求。

“Achilles now plans to undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors, while remaining compliant with Nasdaq and SEC requirements,” the company noted.

该公司指出：“Achilles目前计划采取其他措施，包括进一步减少员工人数和董事会规模，同时保持符合纳斯达克和美国证券交易委员会的要求。”。

TRACERx, a study led by Professor Charles Swanton at University College London (UCL), has collected extensive genetic data from over 3,200 tumor samples from more than 800 lung cancer patients.

TRACERx是由伦敦大学学院（UCL）查尔斯·斯万顿教授领导的一项研究，它从800多名肺癌患者的3200多个肿瘤样本中收集了广泛的遗传数据。

This multi-region, multi-time-point sequencing offers deep insights into cancer evolution and treatment responses.

这种多区域，多时间点测序为癌症进化和治疗反应提供了深入的见解。

As part of the deal, AstraZeneca will also take over Achilles’ Material Acquisition Platform (MAP), which houses tumor samples and data collected from nearly 300 cancer patients across various solid tumor indications such as lung, melanoma and breast cancer.

作为交易的一部分，阿斯利康还将接管Achilles的材料采集平台（MAP），该平台收集了近300名癌症患者的肿瘤样本和数据，这些样本来自各种实体瘤适应症，如肺癌、黑色素瘤和乳腺癌。

“We are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets,” said Dr. Iraj Ali, CEO of Achilles Therapeutics.

“我们很高兴作为肿瘤学的领导者，阿斯利康认识到我们TRACERx和MAP资产的科学价值，”Achilles首席执行官Iraj Ali博士说。

The company believes these assets have significant potential to aid in developing improved cancer therapies.

该公司认为，这些资产在开发改进的癌症疗法方面具有巨大潜力。

Price Action: ACHL shares are trading higher by 7.01% to $1.050 at last check Tuesday.

价格走势：ACHL股价周二上涨7.01%，至1.050美元。